Understanding the experiences of patients, their families and carers is a key element in the decision making process by SMC.

It is important for SMC Committee members to fully understand how a new medicine impacts the quality of life of our patients and carers. This enables them to make a fully informed decision on whether or not to recommend a new medicine.

Patients, members of their families and carers can provide unique knowledge about what it's like to live with a condition. They can explain the advantages and disadvantages of medicines that may not be available in published literature or quality of life measures.

Melanoma UK are proud to work in partnership with the SMC, gather vital information for our patient group submissions and represent the patient voice.